Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis

BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of respiratory infections in children. Palivizumab (PZ) is the only RSV-specific immunoprophylaxis approved by the U.S. Food and Drug Administration. Mutations leading to amino acid substitutions in the PZ binding site of the RSV F prote...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliveira, Danielle B.L., Iwane, Marika K., Prill, Mila M., Weinberg, Geoffrey A., Williams, John V., Griffin, Marie R., Szilagyi, Peter G., Edwards, Kathryn M., Staat, Mary A., Hall, Caroline B., Durigon, Edison L., Erdman, Dean D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172275/
https://www.ncbi.nlm.nih.gov/pubmed/25766983
http://dx.doi.org/10.1016/j.jcv.2015.01.016

Ejemplares similares

Ejemplares similares